Regeneron Pharmaceuticals has announced positive Phase 2 results for two innovative monoclonal antibodies targeting distinct domains of Factor XI. REGN7508, designed to maximize anticoagulant activity while minimizing bleeding risk, targets the catalytic domain, while REGN9933, aimed at patients with the…
Roche has announced results from the Phase IIb PADOVA study investigating prasinezumab in 586 individuals with early-stage Parkinson’s disease. Participants received treatment for a minimum of 18 months while maintaining stable symptomatic therapies. The study’s primary endpoint, time to confirmed…
Viatris announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of cenerimod in adults with moderate-to-severe systemic lupus erythematosus (SLE). The findings, published in Lancet Rheumatology, demonstrated that cenerimod 4 mg provided clinically meaningful and…
Teva Pharmaceuticals and Sanofi today announced that the Phase 2b RELIEVE UCCD study of duvakitug (TEV’574/SAR447189), an anti-TL1A monoclonal antibody, met its primary endpoints for the treatment of moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD). The study, which evaluated…
Bayer announced positive topline results from the global Phase III QUASAR study, which evaluated the efficacy and safety of aflibercept 8 mg in patients with macular edema following retinal vein occlusion (RVO), including central, branch, and hemiretinal vein occlusion. The…
Regeneron Pharmaceuticals, Inc announced today that the Phase 3 QUASAR trial investigating EYLEA HD® (aflibercept) Injection 8 mg has successfully met its primary endpoint. The trial evaluated the treatment of macular edema following retinal vein occlusion (RVO), including central, branch,…
Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., have announced promising results from the RELIEVE UCCD phase 2b study, which met its primary endpoints in patients with ulcerative colitis (UC) and Crohn’s disease (CD). The study…
GSK plc has announced that ViiV Healthcare, the global HIV-focused company majority owned by GSK with Pfizer and Shionogi as shareholders, received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency…
Jazz Pharmaceuticals plc has announced a pivotal leadership transition, as Bruce Cozadd, the company’s Co-Founder, Chairperson, and Chief Executive Officer (CEO), plans to retire from his role upon the appointment of a successor. This transition, expected to conclude by the…
We, the member countries of the Group of Friends of the WHO Academy, reaffirm our steadfast commitment to supporting the WHO Academy as a vital mechanism for enhancing the skills and competencies of human resources for health. This initiative is…
Lupin Digital Health, a wholly owned subsidiary of the global pharmaceutical leader Lupin Limited, has announced a strategic collaboration with Medicover Hospitals to enhance cardiac care for patients in India. This innovative partnership focuses on delivering comprehensive post-operative rehabilitation and…
Lupin Limited, a leading global pharmaceutical company, has announced the acquisition of three key anti-diabetes trademarks—GIBTULIO®, GIBTULIO MET®, and AJADUO®—from Boehringer Ingelheim International GmbH. This strategic move is aimed at strengthening Lupin’s diabetes portfolio in India. According to the terms…